{"title":"β-地中海贫血的新见解","authors":"E. Paubelle, X. Thomas","doi":"10.33590/emjhematol/10314844","DOIUrl":null,"url":null,"abstract":"Thalassaemia is a hereditary cause of hypochromic microcytic anaemia resulting from defects in haemoglobin production. β-thalassaemia, which is caused by a decrease in the production of β-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. This review aims to highlight the significant progress being made in the areas of ineffective erythropoiesis control, metal chelation, and gene therapy, which is bringing new hope and should change patient management and prognosis in the near future.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":"86 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Insights in β-Thalassaemia\",\"authors\":\"E. Paubelle, X. Thomas\",\"doi\":\"10.33590/emjhematol/10314844\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thalassaemia is a hereditary cause of hypochromic microcytic anaemia resulting from defects in haemoglobin production. β-thalassaemia, which is caused by a decrease in the production of β-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. This review aims to highlight the significant progress being made in the areas of ineffective erythropoiesis control, metal chelation, and gene therapy, which is bringing new hope and should change patient management and prognosis in the near future.\",\"PeriodicalId\":326555,\"journal\":{\"name\":\"EMJ Hematology\",\"volume\":\"86 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjhematol/10314844\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjhematol/10314844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Thalassaemia is a hereditary cause of hypochromic microcytic anaemia resulting from defects in haemoglobin production. β-thalassaemia, which is caused by a decrease in the production of β-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. This review aims to highlight the significant progress being made in the areas of ineffective erythropoiesis control, metal chelation, and gene therapy, which is bringing new hope and should change patient management and prognosis in the near future.